期刊文献+

白细胞介素-7选择性剪接变异体的研究 被引量:1

Expression of interleukin-7 mRNA and identification of its splice variants
下载PDF
导出
摘要 目的 寻找人肿瘤细胞选择性的白细胞介素 7(Interleukin 7,IL 7)剪接变异体。方法 运用自行设计的IL 7引物 ,采用逆转录聚合酶链反应 (RT PCR)技术 ,分离正常肝组织、原发肝癌组织、正常胃组织和胃癌组织IL 7mRNA ,再对电泳所获条带进行克隆、测序。结果 正常肝组织、原发肝癌组织、正常胃组织和胃癌组织都能检测到IL 7mRNA ,而且从肝癌组织、胃癌组织中各分离出一条新带 ,经亚克隆及测序 ,证实这两条带分别是人IL 7基因cDNA第 4外显子 (肝癌组织 )和第 5外显子 (胃癌组织 )缺乏所致。结论 肝癌组织和胃癌组织存在不同选择性IL 7剪接变异体。这些变异体的发现 ,为肿瘤病人的免疫调节紊乱以及肿瘤病人的临床免疫治疗提供了新的研究方向。 Objective To investigate the expression of interleukin-7 in human liver and stomach, identify the splice variants of IL-7.Methods Reverse transcription-polymerase chain reaction (RT-PCR) was used for investigating the expression of IL-7. According to IL-7 gene cDNA, the primers were designed and synthesized, then the splice variants of IL-7 in human cancer tissues was identify, cloned into vector and sequenced.Results the results showed that (1)the expression of IL-7 mRNA was nearly equal between human liver and stomach,(2) Two new bands of IL-7 was obtained from liver cancer and gastric carcinoma, one lacks exon 4, another exon 5.Conclusion IL-7 gene is expressed highly in both human liver and stomach . In addition, human liver cancer and gastric carcinoma can produce splicing variants of IL-7 by alternative splicing.
出处 《解剖学研究》 CAS 2004年第1期40-42,共3页 Anatomy Research
关键词 IL-7 胃癌组织 肝癌组织 变异体 白细胞介素-7 原发肝癌 正常 选择性剪接 测序 亚克隆 IL-7 Molecular cloning Sequence analysis Carcinoma Splice variant
  • 相关文献

参考文献12

  • 1Rosenberg SA, Jicha DL, Mule P, et al. Interleukin 7generates antitumor cytitumor T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med, 1991,174:1511~1515.
  • 2Schadenor D, Bhmt M, Mller P, et al. Interleukin-7 induces differential lymphokine activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells. J Invest Dermatol, 1994,102: 838~843.
  • 3Bhmt M, Mller P, Kalbfleisch A, et al. Lysis of allogeneic and autologous melanoma cells by IL-7-induced lyphokine-activated killer cells. Br J Cancer, 1994,70:54~59.
  • 4Korte A, Moricke A, Beyermann B, et al. Extensive alternative splicing of interleukin-7 in malignant hematopoietic cells:implication of distinct isoforms in modulating IL-7 activity. J Interferon Cytokine Res, 1999,19:495~503.
  • 5Grabstein KH, Namen K, Shanebeck RF, et al. Regulation of T cell proliferation by IL-7. J Immunol, 1990,144:3015~3020.
  • 6Lynch DH, Miller RE. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med, 1994, 179:31
  • 7Geiselhart LA, Humphries CA, Gregorio TA, et al. IL-7administration alters the CD4: CD8 ratio, increase T cell numbers, and increase T cell function in the absence of activation. J Immunol,2001,166:3019~3027.
  • 8Witting B, Marten A, Dorbic T, et al. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/Ⅱ trial. Hum Gene Ther,2001,12:267~278.
  • 9Moderk B, Resch A, Grasso C, et al. Genome-wide detection of alternative splicing in expressed sequence of human genes.Nucleic Acids Research, 2001,29: 2850~2853.
  • 10Moderk B, Lee C. A genomic view of alternative splicing.Nature Genetic,2002,30:13~15.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部